Texas Public Radio: Is COVID-19 A Vascular Disease?
UC cardiologist discusses COVID-19 impact on the vascular system
At first, COVID-19 appeared to be primarily a respiratory disease. But patients have reported a much wider range of symptoms than most viral diseases, leading some researchers to wonder if COVID-19 might, in some cases, also be a vascular disease.
Journalists for Texas Public Radio's news podcast Petrie Dish discuss the science of the pandemic. The segment includes an interview with Richard Becker, MD, director of the University of Cincinnati Heart, Lung and Vascular Institute and UC Health physician, along with listening to coronavirus survivors experiencing the vascular side effects of the disease.
Listen to the entire June 27 segment - Becker segment begins 10:57 and continues through 14:11 and another reference at 20-minute mark
Learn more about Becker's latest research on COVID-19.
Read UC stories on heart disease and COVID-19.
Featured image at top: Richard Becker, MD, shown in the UC College of Medicine. Photo/Colleen Kelley/UC Creative + Brand.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.